Susekov A V, Rozhkova T A, Tripoten' M I, Pogorelova O A, Kulev B D, Balakhonova T V, Zubareva M Iu, Masenko V P, Rogozova A N, Kukharchuk V V
Kardiologiia. 2007;47(2):25-30.
To elucidate effect of two doses of atorvastatin (10 and 20 mg/day) on endothelial function, distensibility and stiffness of vascular wall.
Patients (n=50) with documented ischemic heart disease and hyperlipidemia were randomized to 10 or 20 mg/day of atorvastatin (Atoris, KRKA). Endothelial function and common carotid artery wall distensibility and stiffness were assessed at baseline and after 12 and 24 weeks of treatment.
Administration of both 10 and 20 mg/day doses of atorvastatin for 6 weeks was associated with significant lowering of total cholesterol (CH), triglycerides (TG) and low density lipoprotein (LDL) CH (24.5, 18.4, 34.9% and 29.1, 28.2, 40.9%, respectively). After 24 weeks LDL CH lowering from baseline reached 34.9 and 43.9% (p<0.001) and that of TG - 22 and 15%, in 10 and 20 mg/day groups, respectively. There were no significant differences between 10 and 20 mg/day groups in baseline values of endothelium dependent vasodilation (EDV), carotid artery distensibility and stiffness (7.28 and 6.64%, 21.60 and 20.15, 8.04 and 9.19 U, in 10 and 20 mg/day groups, respectively). After 3 months of treatment there occurred significant 38.4% (10 mg/day) and 45.4% (20 mg/day) increases of EDV. Significant 27.6% (10 mg/day) and 28.8% (20 mg/day) enhancement of vascular distensibility was noted after 24 weeks. Vascular wall stiffness decreased 33.4% (p=0.008) and 31.3% (p=0.002) in 10 and 20 mg/day groups, respectively.
阐明两种剂量(10毫克/天和20毫克/天)的阿托伐他汀对血管内皮功能、血管壁扩张性和僵硬度的影响。
将50例确诊为缺血性心脏病和高脂血症的患者随机分为两组,分别给予10毫克/天或20毫克/天的阿托伐他汀(Atoris,KRKA公司生产)。在基线时以及治疗12周和24周后评估内皮功能、颈总动脉壁的扩张性和僵硬度。
给予10毫克/天和20毫克/天剂量的阿托伐他汀治疗6周后,总胆固醇(CH)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-CH)均显著降低(分别为24.5%、18.4%、34.9%和29.1%、28.2%、40.9%)。24周后,10毫克/天和20毫克/天组的LDL-CH较基线分别降低34.9%和43.9%(p<0.001),TG降低22%和15%。10毫克/天组和20毫克/天组在内皮依赖性血管舒张(EDV)、颈动脉扩张性和僵硬度的基线值方面无显著差异(10毫克/天组和20毫克/天组分别为7.28%和6.64%、21.60和20.15、8.04和9.19 U)。治疗3个月后,EDV显著增加,10毫克/天组增加38.4%,20毫克/天组增加45.4%。24周后,血管扩张性显著增强,10毫克/天组增加27.6%,20毫克/天组增加28.8%。10毫克/天组和20毫克/天组的血管壁僵硬度分别降低33.4%(p=0.008)和31.3%(p=0.002)。